Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes
- PMID: 9416986
- DOI: 10.1038/sj.jhh.1000533
Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes
Abstract
The aim of this double-blind, parallel group study was to compare the effects of nebivolol and atenolol on blood pressure (BP) and insulin sensitivity in hypertensive patients with type II, non-insulin dependent diabetes mellitus (NIDDM). After a 4-week run-in period on placebo, 30 patients (14 males and 16 females) aged 43 to 69 years, with stable NIDDM and mild to moderate hypertension (DBP > or =95 and <116 mm Hg) were randomised to receive either nebivolol 5 mg or atenolol 50 mg, both administered once daily for 6 months. At the end of the placebo and the active treatment periods, supine and standing BP was measured, 24-h urinary C-peptide, HbA1c, plasma glucose and lipid levels were evaluated and an euglycaemic hyperinsulinaemic clamp was performed to evaluate insulin sensitivity: glucose infusion rate during the last 60 min of clamp and total glucose requirements were evaluated. Nebivolol 5 mg once daily was of an equivalent efficacy as atenolol 50 mg once daily at reducing supine and standing systolic and diastolic BP values. Neither beta-blocker adversely affected carbohydrate metabolism in terms of insulin sensitivity, whole body glucose utilization, HbA1c and 24-h urinary C-peptide excretion. No significant changes in cholesterol (total, high density and low density lipoprotein) and triglycerides plasma levels were observed with both beta-blockers. These findings indicate that, in hypertensive patients with NIDDM, ie, in subjects who have established insulin resistance, treatment with nebivolol and atenolol neither further deteriorated insulin sensitivity nor adversely affected the lipid profile.
Similar articles
-
Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.Am J Ther. 1999 May;6(3):137-47. doi: 10.1097/00045391-199905000-00004. Am J Ther. 1999. PMID: 10423656 Clinical Trial.
-
Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.J Hypertens. 2001 Aug;19(8):1429-35. doi: 10.1097/00004872-200108000-00011. J Hypertens. 2001. PMID: 11518851 Clinical Trial.
-
Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.Clin Exp Hypertens. 1993 May;15(3):501-9. doi: 10.3109/10641969309041625. Clin Exp Hypertens. 1993. PMID: 8098243 Clinical Trial.
-
Nebivolol in the management of essential hypertension: a review.Drugs. 1999 Apr;57(4):633-51. doi: 10.2165/00003495-199957040-00011. Drugs. 1999. PMID: 10235696 Review.
-
Nebivolol: a third-generation beta-blocker for hypertension.Clin Ther. 2009 Mar;31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007. Clin Ther. 2009. PMID: 19393838 Review.
Cited by
-
Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia.Drug Des Devel Ther. 2020 Nov 17;14:5005-5017. doi: 10.2147/DDDT.S280055. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33235439 Free PMC article. Clinical Trial.
-
A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension.J Clin Hypertens (Greenwich). 2007 Sep;9(9):667-76. doi: 10.1111/j.1524-6175.2007.06679.x. J Clin Hypertens (Greenwich). 2007. PMID: 17786067 Free PMC article. Clinical Trial.
-
Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension.J Clin Diagn Res. 2014 Jun;8(6):HC01-4. doi: 10.7860/JCDR/2014/7728.4419. Epub 2014 Jun 20. J Clin Diagn Res. 2014. PMID: 25120998 Free PMC article.
-
Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes.J Clin Hypertens (Greenwich). 2013 Apr;15(4):270-8. doi: 10.1111/jch.12071. Epub 2013 Feb 1. J Clin Hypertens (Greenwich). 2013. PMID: 23551727 Free PMC article. Clinical Trial.
-
Nebivolol: a review of its use in the management of hypertension and chronic heart failure.Drugs. 2006;66(10):1389-409; discussion 1410. doi: 10.2165/00003495-200666100-00007. Drugs. 2006. PMID: 16903772 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical